{"count":32,"next":"https://lda.gov/api/v1/filings/?filing_specific_lobbying_issues=H.R.+6130&filing_year=2026&ordering=-filing_year&page=2","previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/42566dc4-ba29-4e41-a15b-7bedf724237f/","filing_uuid":"42566dc4-ba29-4e41-a15b-7bedf724237f","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/42566dc4-ba29-4e41-a15b-7bedf724237f/print/","filing_document_content_type":"text/html","income":null,"expenses":"200000.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"DAVID WIERMANSKI","dt_posted":"2026-04-02T15:12:56-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th Street, NW","registrant_address_2":"SUITE 500","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":17933,"url":"https://lda.gov/api/v1/registrants/17933/","house_registrant_id":31263,"name":"HEALTHCARE LEADERSHIP COUNCIL","description":null,"address_1":"750 9th Street, NW","address_2":"SUITE 500","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVID WIERMANSKI","contact_telephone":"","dt_updated":"2026-07-14T08:39:44.484618-04:00"},"client":{"id":123360,"url":"https://lda.gov/api/v1/clients/123360/","client_id":12,"name":"HEALTHCARE LEADERSHIP COUNCIL","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 4464/ S. 3204, Preventive Health Savings Act H.R. 5145, S. 3385, Bipartisan Premium Tax Credit Extension Act H.R. 5283/S. 2759, Healthcare Workforce Resilience Act S. 2824, A bill to amend the Internal Revenue Code of 1986 to extend the temporary enhanced premium credits. U.S. Department of Education Negotiated Rulemaking Committees [Docket ID ED-2025-OPE-0151-0001] U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) U.S Department of Health and Human Services, Centers for Medicare & Medicaid ServicesAdvance Notice of Methodological Changes for Calendar Year (CY) 2027 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2026-0034) U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity (HTI-5) Proposed Rule (RIN 0955-AA09) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care (RIN 0955-AA13)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145902,"prefix":null,"prefix_display":null,"first_name":"MARIA","nickname":null,"middle_name":null,"last_name":"GHAZAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145905,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145906,"prefix":null,"prefix_display":null,"first_name":"CLARA","nickname":null,"middle_name":null,"last_name":"KEANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147562,"prefix":null,"prefix_display":null,"first_name":"SEAN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153247,"prefix":null,"prefix_display":null,"first_name":"ANGELA","nickname":null,"middle_name":null,"last_name":"BANKS DUNCAN","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 3164/S. 2426, Ensuring Community Access to Pharmacist Services Act H.R. 4093, S. 3848, Apples to Apples Comparison Act H.R. 4731/S. 2439, Resident Physician Shortage Reduction Act H.R. 6010/S. 1105, No UPCODE Act H.R. 6130/ S. 3267, Alzheimers Screening and Prevention Act U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) U.S Department of Health and Human Services, Centers for Medicare & Medicaid ServicesAdvance Notice of Methodological Changes for Calendar Year (CY) 2027 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2026-0034) U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity (HTI-5) Proposed Rule (RIN 0955-AA09) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care (RIN 0955-AA13)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145902,"prefix":null,"prefix_display":null,"first_name":"MARIA","nickname":null,"middle_name":null,"last_name":"GHAZAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145905,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145906,"prefix":null,"prefix_display":null,"first_name":"CLARA","nickname":null,"middle_name":null,"last_name":"KEANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147562,"prefix":null,"prefix_display":null,"first_name":"SEAN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153247,"prefix":null,"prefix_display":null,"first_name":"ANGELA","nickname":null,"middle_name":null,"last_name":"BANKS DUNCAN","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/ae8c5c84-c5f0-40fa-ad6f-02b549499069/","filing_uuid":"ae8c5c84-c5f0-40fa-ad6f-02b549499069","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/ae8c5c84-c5f0-40fa-ad6f-02b549499069/print/","filing_document_content_type":"text/html","income":null,"expenses":"190000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-04-16T12:48:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2026 and FY 2027 appropriations legislation, including advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, beneficiary protections, and the CY 2027 Advance Notice.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/ae8c5c84-c5f0-40fa-ad6f-02b549499069/","filing_uuid":"ae8c5c84-c5f0-40fa-ad6f-02b549499069","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/ae8c5c84-c5f0-40fa-ad6f-02b549499069/print/","filing_document_content_type":"text/html","income":null,"expenses":"190000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-04-16T12:48:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2026 and FY 2027 appropriations legislation, including advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, beneficiary protections, and the CY 2027 Advance Notice.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/3a7a812d-63a4-4f94-be5b-966857ce4bd4/","filing_uuid":"3a7a812d-63a4-4f94-be5b-966857ce4bd4","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/3a7a812d-63a4-4f94-be5b-966857ce4bd4/print/","filing_document_content_type":"text/html","income":null,"expenses":"120000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"M'liss Reingruber","dt_posted":"2026-04-20T09:46:36-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"5614 Connecticut Ave NW #288","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20015","registrant":{"id":401105571,"url":"https://lda.gov/api/v1/registrants/401105571/","house_registrant_id":null,"name":"USAGAINSTALZHEIMERS ACTION","description":"Advocacy organization","address_1":"5614 Connecticut Ave NW #288","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20015","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"M'LISS REINGRUBER","contact_telephone":"+1 202-349-3803","dt_updated":"2026-07-22T10:55:30.938145-04:00"},"client":{"id":206248,"url":"https://lda.gov/api/v1/clients/206248/","client_id":12,"name":"USAGAINSTALZHEIMERS ACTION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-07-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 7147, H.R. 7148 - Consolidated Appropriations Act; Issues related to the Presidents FY2027 Budget Proposal; Issues related to funding for NIH; Issues related to funding for CDC; Issues related to funding for CMS; Issues related to funding for Alzheimer's research","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151708,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"SWARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 3501, S. 1799 - a bill to amend title XVIII of the Social Security Act to direct CMS to include certain standardized tests for cognitive impairment detection in the Medicare annual wellness visit and initial preventive physical examination; H.R. 5371 - FY2026 Continuing Appropriations and Extensions Act; H.R. 6799 - To amend title II of the Social Security Act to eliminate the waiting periods for disability insurance benefits and Medicare coverage for individuals with young-onset Alzheimer's, and for other purposes; H.R. 6130, S. 3267 - ASAP Act; Issues related to the extension of the enhanced advanced premium tax credits; Issues related to the Affordable Care Act and comprehensive healthcare","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151708,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"SWARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 247, S. 46 - Health Care Affordability Act of 2025; H.R. 6799 - To amend title II of the Social Security Act to eliminate the waiting periods for disability insurance benefits and Medicare coverage for individuals with young-onset Alzheimer's, and for other purposes; Issues related to improving strategies for early detection and prevention of Alzheimers; Issues related to the Affordable Care Act and comprehensive healthcare","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151708,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"SWARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/f5b60623-0bb5-49f9-8407-6cb2d687473d/","filing_uuid":"f5b60623-0bb5-49f9-8407-6cb2d687473d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/f5b60623-0bb5-49f9-8407-6cb2d687473d/print/","filing_document_content_type":"text/html","income":null,"expenses":"690000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Sherry H. Widicus","dt_posted":"2026-04-20T12:59:25-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 Plaza Drive","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Secaucus","registrant_state":"NJ","registrant_zip":"07094","registrant":{"id":32555,"url":"https://lda.gov/api/v1/registrants/32555/","house_registrant_id":33894,"name":"QUEST DIAGNOSTICS INCORPORATED","description":"Provide medical clinical laboratory testing.","address_1":"500 Plaza Drive","address_2":null,"address_3":null,"address_4":null,"city":"Secaucus","state":"NJ","state_display":"New Jersey","zip":"07094","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SHERRY H. WIDICUS","contact_telephone":"+1 800-222-0446","dt_updated":"2026-07-24T11:03:57.719266-04:00"},"client":{"id":140705,"url":"https://lda.gov/api/v1/clients/140705/","client_id":12,"name":"QUEST DIAGNOSTICS INCORPORATED","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-07-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Federal policy related to strengthening the clinical laboratory workforce S. 2355 and H.R. 5582 - Patients Deserve Price Tags Act S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":79438,"prefix":null,"prefix_display":null,"first_name":"SHERRY","nickname":null,"middle_name":"HARPER","last_name":"WIDICUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139227,"prefix":null,"prefix_display":null,"first_name":"EMMA","nickname":null,"middle_name":null,"last_name":"LANGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":79438,"prefix":null,"prefix_display":null,"first_name":"SHERRY","nickname":null,"middle_name":"HARPER","last_name":"WIDICUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139227,"prefix":null,"prefix_display":null,"first_name":"EMMA","nickname":null,"middle_name":null,"last_name":"LANGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act H.R. 6130 - Alzheimers Screening and Prevention Act of 2025 Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":79438,"prefix":null,"prefix_display":null,"first_name":"SHERRY","nickname":null,"middle_name":"HARPER","last_name":"WIDICUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139227,"prefix":null,"prefix_display":null,"first_name":"EMMA","nickname":null,"middle_name":null,"last_name":"LANGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e8e7b414-e066-4ab6-a68c-95ef70ab621c/","filing_uuid":"e8e7b414-e066-4ab6-a68c-95ef70ab621c","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/e8e7b414-e066-4ab6-a68c-95ef70ab621c/print/","filing_document_content_type":"text/html","income":null,"expenses":"600000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-04-20T13:55:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/2e772a20-fb1d-481d-bfdd-3772e1b61812/","filing_uuid":"2e772a20-fb1d-481d-bfdd-3772e1b61812","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/2e772a20-fb1d-481d-bfdd-3772e1b61812/print/","filing_document_content_type":"text/html","income":null,"expenses":"60000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Adina Lasser","dt_posted":"2026-04-20T15:31:21-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2033 K Street NW","registrant_address_2":"Suite 450","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401010854,"url":"https://lda.gov/api/v1/registrants/401010854/","house_registrant_id":42171,"name":"ALLIANCE FOR AGING RESEARCH","description":"Non-profit healthcare advocacy organization","address_1":"2033 K Street NW","address_2":"Suite 450","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SCOTT FREY","contact_telephone":"+1 571-289-1385","dt_updated":"2026-09-24T12:38:43.419803-04:00"},"client":{"id":196811,"url":"https://lda.gov/api/v1/clients/196811/","client_id":12,"name":"ALLIANCE FOR AGING RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-05-04"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/ffa88e50-9459-4df5-a323-7360719ad7ae/","filing_uuid":"ffa88e50-9459-4df5-a323-7360719ad7ae","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/ffa88e50-9459-4df5-a323-7360719ad7ae/print/","filing_document_content_type":"text/html","income":null,"expenses":"70000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Scott Frey","dt_posted":"2026-07-16T20:52:48-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2033 K Street NW","registrant_address_2":"Suite 450","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401010854,"url":"https://lda.gov/api/v1/registrants/401010854/","house_registrant_id":42171,"name":"ALLIANCE FOR AGING RESEARCH","description":"Non-profit healthcare advocacy organization","address_1":"2033 K Street NW","address_2":"Suite 450","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SCOTT FREY","contact_telephone":"+1 571-289-1385","dt_updated":"2026-09-24T12:38:43.419803-04:00"},"client":{"id":196811,"url":"https://lda.gov/api/v1/clients/196811/","client_id":12,"name":"ALLIANCE FOR AGING RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-05-04"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -Message support for Rare Disease Clinical Trials Improvements","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program -FY 27 Appropriations H.R. 9260 and pending Senate bill, Increase Funding for Programs benefitting older adults at HHS, including ASPE, NIH, CDC HRSA, ARHQ, FDA, CMS, ACL","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/cd8cbe49-569a-4b7a-b4d9-35a57eafeba2/","filing_uuid":"cd8cbe49-569a-4b7a-b4d9-35a57eafeba2","filing_type":"2A","filing_type_display":"2nd Quarter - Amendment","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/cd8cbe49-569a-4b7a-b4d9-35a57eafeba2/print/","filing_document_content_type":"text/html","income":null,"expenses":"70000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Scott Frey","dt_posted":"2026-07-16T21:11:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2033 K Street NW","registrant_address_2":"Suite 450","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401010854,"url":"https://lda.gov/api/v1/registrants/401010854/","house_registrant_id":42171,"name":"ALLIANCE FOR AGING RESEARCH","description":"Non-profit healthcare advocacy organization","address_1":"2033 K Street NW","address_2":"Suite 450","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SCOTT FREY","contact_telephone":"+1 571-289-1385","dt_updated":"2026-09-24T12:38:43.419803-04:00"},"client":{"id":196811,"url":"https://lda.gov/api/v1/clients/196811/","client_id":12,"name":"ALLIANCE FOR AGING RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-05-04"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program -FY 27 Appropriations H.R. 9260 and pending Senate bill, Increase Funding for Programs benefitting older adults at HHS, including ASPE, NIH, CDC HRSA, ARHQ, FDA, CMS, ACL","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401) -End Coverage with Evidence Development for Alzheimer's Medications and TAVR","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4150fb21-6764-4629-a6d9-ed58dd4a4200/","filing_uuid":"4150fb21-6764-4629-a6d9-ed58dd4a4200","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4150fb21-6764-4629-a6d9-ed58dd4a4200/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-07-17T10:20:36-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4150fb21-6764-4629-a6d9-ed58dd4a4200/","filing_uuid":"4150fb21-6764-4629-a6d9-ed58dd4a4200","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4150fb21-6764-4629-a6d9-ed58dd4a4200/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-07-17T10:20:36-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a8efa44d-37e9-4224-ab4f-baf4c2c2f9aa/","filing_uuid":"a8efa44d-37e9-4224-ab4f-baf4c2c2f9aa","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/a8efa44d-37e9-4224-ab4f-baf4c2c2f9aa/print/","filing_document_content_type":"text/html","income":null,"expenses":"130000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"M'liss Reingruber","dt_posted":"2026-07-20T11:51:15-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"5614 Connecticut Ave NW #288","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20015","registrant":{"id":401105571,"url":"https://lda.gov/api/v1/registrants/401105571/","house_registrant_id":null,"name":"USAGAINSTALZHEIMERS ACTION","description":"Advocacy organization","address_1":"5614 Connecticut Ave NW #288","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20015","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"M'LISS REINGRUBER","contact_telephone":"+1 202-349-3803","dt_updated":"2026-07-22T10:55:30.938145-04:00"},"client":{"id":206248,"url":"https://lda.gov/api/v1/clients/206248/","client_id":12,"name":"USAGAINSTALZHEIMERS ACTION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-07-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 9495 - Department of Defense Appropriations Act, 2027; H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; S. 4632 - Lankford-Hassan Prevent Government Shutdowns Act of 2026; Issues related to funding for NIH; Issues related to funding for CDC; Issues related to funding for CMS; Issues related to funding for Alzheimer's","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151708,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"SWARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 3501, S. 1799 - a bill to amend title XVIII of the Social Security Act to direct CMS to include certain standardized tests for cognitive impairment detection in the Medicare annual wellness visit and initial preventive physical examination; H.R. 5371 - FY2026 Continuing Appropriations and Extensions Act; H.R. 6799 - To amend title II of the Social Security Act to eliminate the waiting periods for disability insurance benefits and Medicare coverage for individuals with young-onset Alzheimer's, and for other purposes; H.R. 6130, S. 3267 - ASAP Act; H.R. 9418 - Access to Innovative Treatments Act of 2026; H.R. 9495 - Department of Defense Appropriations Act, 2027; H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Durbin Cures Act; Issues related to the Affordable Care Act, Medicaid and comprehensive healthcare; Issues related to implementation of PL-119-21; Issues related to coverage for biomarker testing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151708,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"SWARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 247, S. 46 - Health Care Affordability Act of 2025; H.R. 9495 - Department of Defense Appropriations Act, 2027; H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R. 9418 - Access to Innovative Treatments Act of 2026; H.R. 6799 - To amend title II of the Social Security Act to eliminate the waiting periods for disability insurance benefits and Medicare coverage for individuals with young-onset Alzheimer's, and for other purposes; Issues related to improving strategies for early detection and prevention of Alzheimers; Issues related to the Affordable Care Act, Medicaid and comprehensive healthcare; Issues related to implementation of PL-119-21; Issues related to coverage for biomarker testing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151708,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"SWARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/2a646143-1af0-4270-aa15-6008eac603eb/","filing_uuid":"2a646143-1af0-4270-aa15-6008eac603eb","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/2a646143-1af0-4270-aa15-6008eac603eb/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Donald Walker","dt_posted":"2026-07-20T12:26:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"525 9th St NW, 7th Floor","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":61458,"url":"https://lda.gov/api/v1/registrants/61458/","house_registrant_id":35394,"name":"THE RABEN GROUP","description":"National public affairs and strategic communications firm","address_1":"525 9th Street NW","address_2":"7th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT RABEN","contact_telephone":"+1 202-466-8585","dt_updated":"2026-07-17T13:07:21.783630-04:00"},"client":{"id":161639,"url":"https://lda.gov/api/v1/clients/161639/","client_id":137,"name":"COMPASSION & CHOICES","general_description":"​ensure healthcare providers honor and enable patients decisions about their care","client_government_entity":false,"client_self_select":false,"state":"CO","state_display":"Colorado","country":"US","country_display":"United States of America","ppb_state":"CO","ppb_state_display":"Colorado","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-03-13"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation to improve care at the end of life; including H.R. 4313 / S. 2237; PCHETA (S. 2287/H.R.4425); Improving Access to Advance Care Planning Act (S.2865); Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130); Medicare Advance Planning (MAP) for Care Act (S. 3473).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63119,"prefix":null,"prefix_display":null,"first_name":"EDUARDO","nickname":null,"middle_name":null,"last_name":"SOTO","suffix":null,"suffix_display":null},"covered_position":"Legislative Aide, Maxine Waters' office; intern, Office of Resident commissioner Pedro Pierluisi","new":false},{"lobbyist":{"id":96704,"prefix":null,"prefix_display":null,"first_name":"SHAPRI","nickname":null,"middle_name":null,"last_name":"LOMAGLIO","suffix":null,"suffix_display":null},"covered_position":"legal fellow, Office of Senator Jon Kyl","new":false},{"lobbyist":{"id":149772,"prefix":null,"prefix_display":null,"first_name":"PRECIOUS","nickname":null,"middle_name":null,"last_name":"AIMUFUA-AGBONTAEN","suffix":null,"suffix_display":null},"covered_position":"Intern, Congresswoman Yvette D. Clarke (D-NY-09)","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DOC","general_issue_code_display":"District of Columbia","description":"Legislation to improve care at the end of life; including H.R. 4313 / S. 2237; PCHETA (S. 2287/H.R.4425); Improving Access to Advance Care Planning Act (S.2865); Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130); Medicare Advance Planning (MAP) for Care Act (S. 3473).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63119,"prefix":null,"prefix_display":null,"first_name":"EDUARDO","nickname":null,"middle_name":null,"last_name":"SOTO","suffix":null,"suffix_display":null},"covered_position":"Legislative Aide, Maxine Waters' office; intern, Office of Resident commissioner Pedro Pierluisi","new":false},{"lobbyist":{"id":96704,"prefix":null,"prefix_display":null,"first_name":"SHAPRI","nickname":null,"middle_name":null,"last_name":"LOMAGLIO","suffix":null,"suffix_display":null},"covered_position":"legal fellow, Office of Senator Jon Kyl","new":false},{"lobbyist":{"id":149772,"prefix":null,"prefix_display":null,"first_name":"PRECIOUS","nickname":null,"middle_name":null,"last_name":"AIMUFUA-AGBONTAEN","suffix":null,"suffix_display":null},"covered_position":"Intern, Congresswoman Yvette D. Clarke (D-NY-09)","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/2a646143-1af0-4270-aa15-6008eac603eb/","filing_uuid":"2a646143-1af0-4270-aa15-6008eac603eb","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/2a646143-1af0-4270-aa15-6008eac603eb/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Donald Walker","dt_posted":"2026-07-20T12:26:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"525 9th St NW, 7th Floor","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":61458,"url":"https://lda.gov/api/v1/registrants/61458/","house_registrant_id":35394,"name":"THE RABEN GROUP","description":"National public affairs and strategic communications firm","address_1":"525 9th Street NW","address_2":"7th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT RABEN","contact_telephone":"+1 202-466-8585","dt_updated":"2026-07-17T13:07:21.783630-04:00"},"client":{"id":161639,"url":"https://lda.gov/api/v1/clients/161639/","client_id":137,"name":"COMPASSION & CHOICES","general_description":"​ensure healthcare providers honor and enable patients decisions about their care","client_government_entity":false,"client_self_select":false,"state":"CO","state_display":"Colorado","country":"US","country_display":"United States of America","ppb_state":"CO","ppb_state_display":"Colorado","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-03-13"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation to improve care at the end of life; including H.R. 4313 / S. 2237; PCHETA (S. 2287/H.R.4425); Improving Access to Advance Care Planning Act (S.2865); Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130); Medicare Advance Planning (MAP) for Care Act (S. 3473).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63119,"prefix":null,"prefix_display":null,"first_name":"EDUARDO","nickname":null,"middle_name":null,"last_name":"SOTO","suffix":null,"suffix_display":null},"covered_position":"Legislative Aide, Maxine Waters' office; intern, Office of Resident commissioner Pedro Pierluisi","new":false},{"lobbyist":{"id":96704,"prefix":null,"prefix_display":null,"first_name":"SHAPRI","nickname":null,"middle_name":null,"last_name":"LOMAGLIO","suffix":null,"suffix_display":null},"covered_position":"legal fellow, Office of Senator Jon Kyl","new":false},{"lobbyist":{"id":149772,"prefix":null,"prefix_display":null,"first_name":"PRECIOUS","nickname":null,"middle_name":null,"last_name":"AIMUFUA-AGBONTAEN","suffix":null,"suffix_display":null},"covered_position":"Intern, Congresswoman Yvette D. Clarke (D-NY-09)","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DOC","general_issue_code_display":"District of Columbia","description":"Legislation to improve care at the end of life; including H.R. 4313 / S. 2237; PCHETA (S. 2287/H.R.4425); Improving Access to Advance Care Planning Act (S.2865); Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130); Medicare Advance Planning (MAP) for Care Act (S. 3473).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63119,"prefix":null,"prefix_display":null,"first_name":"EDUARDO","nickname":null,"middle_name":null,"last_name":"SOTO","suffix":null,"suffix_display":null},"covered_position":"Legislative Aide, Maxine Waters' office; intern, Office of Resident commissioner Pedro Pierluisi","new":false},{"lobbyist":{"id":96704,"prefix":null,"prefix_display":null,"first_name":"SHAPRI","nickname":null,"middle_name":null,"last_name":"LOMAGLIO","suffix":null,"suffix_display":null},"covered_position":"legal fellow, Office of Senator Jon Kyl","new":false},{"lobbyist":{"id":149772,"prefix":null,"prefix_display":null,"first_name":"PRECIOUS","nickname":null,"middle_name":null,"last_name":"AIMUFUA-AGBONTAEN","suffix":null,"suffix_display":null},"covered_position":"Intern, Congresswoman Yvette D. Clarke (D-NY-09)","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5ad8f848-d4e0-4bdf-b014-99812a46595b/","filing_uuid":"5ad8f848-d4e0-4bdf-b014-99812a46595b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/5ad8f848-d4e0-4bdf-b014-99812a46595b/print/","filing_document_content_type":"text/html","income":null,"expenses":"700000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-07-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7ba229b3-435d-4ecd-a51a-018dfd969e12/","filing_uuid":"7ba229b3-435d-4ecd-a51a-018dfd969e12","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7ba229b3-435d-4ecd-a51a-018dfd969e12/print/","filing_document_content_type":"text/html","income":null,"expenses":"790000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Tricia Brooks","dt_posted":"2026-07-20T12:58:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"200 Metro Boulevard","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Nutley","registrant_state":"NJ","registrant_zip":"07110","registrant":{"id":400321512,"url":"https://lda.gov/api/v1/registrants/400321512/","house_registrant_id":40258,"name":"EISAI INC.","description":"Pharmaceutical development, manufacturing and distribution -- Health Care","address_1":"200 Metro Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Nutley","state":"NJ","state_display":"New Jersey","zip":"07110","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TRICIA BROOKS","contact_telephone":"+1 202-934-3735","dt_updated":"2026-07-22T11:30:31.993646-04:00"},"client":{"id":189281,"url":"https://lda.gov/api/v1/clients/189281/","client_id":12,"name":"EISAI INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-01-28"},"lobbying_activities":[{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Supply chain manufacturing and tariffs, including: the Section 232 and Section 301 tariff investigations related to branded pharmaceuticals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138282,"prefix":"ms","prefix_display":"MS.","first_name":"TRICIA","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146248,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MAJOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146249,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Pharmaceutical Intellectual Property (IP), including: S. 2658, Medication Affordability and Patent Integrity Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138282,"prefix":"ms","prefix_display":"MS.","first_name":"TRICIA","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146248,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MAJOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146249,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Pharmaceutical manufacturing.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138282,"prefix":"ms","prefix_display":"MS.","first_name":"TRICIA","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146248,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MAJOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146249,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; Pharmacy Benefit Manager (PBM) reform, 340B Drug Discount Program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138282,"prefix":"ms","prefix_display":"MS.","first_name":"TRICIA","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146248,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MAJOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146249,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"General Medicare and Medicaid including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; Center for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers Screening and Prevention (ASAP) Act; H.R. 4752 / S. 2379, the Concentrating on High-value Alzheimers Needs to Get to an End (CHANGE) Act; H.R. 3747, the Accelerating Access to Dementia and Alzheimers Provider Training (AADAPT) Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138282,"prefix":"ms","prefix_display":"MS.","first_name":"TRICIA","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146249,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146248,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MAJOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax reform, including: H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138282,"prefix":"ms","prefix_display":"MS.","first_name":"TRICIA","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146248,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MAJOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146249,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"BROOKS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d6d8ae0f-403c-4233-944d-0dc4af0cf8ca/","filing_uuid":"d6d8ae0f-403c-4233-944d-0dc4af0cf8ca","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/d6d8ae0f-403c-4233-944d-0dc4af0cf8ca/print/","filing_document_content_type":"text/html","income":null,"expenses":"470000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Sherry H. Widicus","dt_posted":"2026-07-20T14:31:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 Plaza Drive","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Secaucus","registrant_state":"NJ","registrant_zip":"07094","registrant":{"id":32555,"url":"https://lda.gov/api/v1/registrants/32555/","house_registrant_id":33894,"name":"QUEST DIAGNOSTICS INCORPORATED","description":"Provide medical clinical laboratory testing.","address_1":"500 Plaza Drive","address_2":null,"address_3":null,"address_4":null,"city":"Secaucus","state":"NJ","state_display":"New Jersey","zip":"07094","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SHERRY H. WIDICUS","contact_telephone":"+1 800-222-0446","dt_updated":"2026-07-24T11:03:57.719266-04:00"},"client":{"id":140705,"url":"https://lda.gov/api/v1/clients/140705/","client_id":12,"name":"QUEST DIAGNOSTICS INCORPORATED","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-07-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Appropriations related to clinical laboratory workforce, PFAS, and cardiovascular disease testing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":79438,"prefix":null,"prefix_display":null,"first_name":"SHERRY","nickname":null,"middle_name":"HARPER","last_name":"WIDICUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139227,"prefix":null,"prefix_display":null,"first_name":"EMMA","nickname":null,"middle_name":null,"last_name":"LANGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 5444 - Medical Laboratory Personnel Shortage Relief Act of 2025 H.R. 7961 - Physicians and Healthcare Workforce Act S. 2355/H.R. 5582 - Patients Deserve Price Tags Act H.R. 9393 - Lower Costs, More Transparency Act of 2026 Federal policies related to prior authorization for medical services S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 H.R. 8890 - The Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act of 2026 H.R. 8413 - SECURE Data Act CMS HealthTech Ecosystem and Interoperability AI policies related to health care","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":79438,"prefix":null,"prefix_display":null,"first_name":"SHERRY","nickname":null,"middle_name":"HARPER","last_name":"WIDICUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139227,"prefix":null,"prefix_display":null,"first_name":"EMMA","nickname":null,"middle_name":null,"last_name":"LANGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act H.R. 6130 - Alzheimers Screening and Prevention Act of 2025 Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":79438,"prefix":null,"prefix_display":null,"first_name":"SHERRY","nickname":null,"middle_name":"HARPER","last_name":"WIDICUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139227,"prefix":null,"prefix_display":null,"first_name":"EMMA","nickname":null,"middle_name":null,"last_name":"LANGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/c6060d9e-8ef2-44aa-8a08-702a00dba278/","filing_uuid":"c6060d9e-8ef2-44aa-8a08-702a00dba278","filing_type":"2A","filing_type_display":"2nd Quarter - Amendment","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/c6060d9e-8ef2-44aa-8a08-702a00dba278/print/","filing_document_content_type":"text/html","income":null,"expenses":"200000.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"DAVID WIERMANSKI","dt_posted":"2026-07-29T09:02:49-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th Street, NW","registrant_address_2":"SUITE 500","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":17933,"url":"https://lda.gov/api/v1/registrants/17933/","house_registrant_id":31263,"name":"HEALTHCARE LEADERSHIP COUNCIL","description":null,"address_1":"750 9th Street, NW","address_2":"SUITE 500","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVID WIERMANSKI","contact_telephone":"","dt_updated":"2026-07-14T08:39:44.484618-04:00"},"client":{"id":123360,"url":"https://lda.gov/api/v1/clients/123360/","client_id":12,"name":"HEALTHCARE LEADERSHIP COUNCIL","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 4464/ S. 3204, Preventive Health Savings Act H.R. 5145, S. 3385, Bipartisan Premium Tax Credit Extension Act H.R. 5283/S. 2759, Healthcare Workforce Resilience Act S. 2824, A bill to amend the Internal Revenue Code of 1986 to extend the temporary enhanced premium credits. U.S. Department of Education Negotiated Rulemaking Committees [Docket ID ED-2025-OPE-0151-0001] U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) U.S Department of Health and Human Services, Centers for Medicare & Medicaid ServicesAdvance Notice of Methodological Changes for Calendar Year (CY) 2027 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2026-0034) U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity (HTI-5) Proposed Rule (RIN 0955-AA09) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care (RIN 0955-AA13)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147562,"prefix":null,"prefix_display":null,"first_name":"SEAN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145902,"prefix":null,"prefix_display":null,"first_name":"MARIA","nickname":null,"middle_name":null,"last_name":"GHAZAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145905,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145906,"prefix":null,"prefix_display":null,"first_name":"CLARA","nickname":null,"middle_name":null,"last_name":"KEANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 3164/S. 2426, Ensuring Community Access to Pharmacist Services Act H.R. 4093, S. 3848, Apples to Apples Comparison Act H.R. 4731/S. 2439, Resident Physician Shortage Reduction Act H.R. 6010/S. 1105, No UPCODE Act H.R. 6130/ S. 3267, Alzheimers Screening and Prevention Act U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) U.S Department of Health and Human Services, Centers for Medicare & Medicaid ServicesAdvance Notice of Methodological Changes for Calendar Year (CY) 2027 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2026-0034) U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity (HTI-5) Proposed Rule (RIN 0955-AA09) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care (RIN 0955-AA13)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145902,"prefix":null,"prefix_display":null,"first_name":"MARIA","nickname":null,"middle_name":null,"last_name":"GHAZAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145905,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145906,"prefix":null,"prefix_display":null,"first_name":"CLARA","nickname":null,"middle_name":null,"last_name":"KEANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147562,"prefix":null,"prefix_display":null,"first_name":"SEAN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a7c4f251-0abc-4a02-a329-318718705421/","filing_uuid":"a7c4f251-0abc-4a02-a329-318718705421","filing_type":"1A","filing_type_display":"1st Quarter - Amendment","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/a7c4f251-0abc-4a02-a329-318718705421/print/","filing_document_content_type":"text/html","income":null,"expenses":"200000.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"DAVID WIERMANSKI","dt_posted":"2026-07-29T09:07:00-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th Street, NW","registrant_address_2":"SUITE 500","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":17933,"url":"https://lda.gov/api/v1/registrants/17933/","house_registrant_id":31263,"name":"HEALTHCARE LEADERSHIP COUNCIL","description":null,"address_1":"750 9th Street, NW","address_2":"SUITE 500","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVID WIERMANSKI","contact_telephone":"","dt_updated":"2026-07-14T08:39:44.484618-04:00"},"client":{"id":123360,"url":"https://lda.gov/api/v1/clients/123360/","client_id":12,"name":"HEALTHCARE LEADERSHIP COUNCIL","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 4464/ S. 3204, Preventive Health Savings Act H.R. 5145, S. 3385, Bipartisan Premium Tax Credit Extension Act H.R. 5283/S. 2759, Healthcare Workforce Resilience Act S. 2824, A bill to amend the Internal Revenue Code of 1986 to extend the temporary enhanced premium credits. U.S. Department of Education Negotiated Rulemaking Committees [Docket ID ED-2025-OPE-0151-0001] U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) U.S Department of Health and Human Services, Centers for Medicare & Medicaid ServicesAdvance Notice of Methodological Changes for Calendar Year (CY) 2027 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2026-0034) U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity (HTI-5) Proposed Rule (RIN 0955-AA09) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care (RIN 0955-AA13)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145906,"prefix":null,"prefix_display":null,"first_name":"CLARA","nickname":null,"middle_name":null,"last_name":"KEANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147562,"prefix":null,"prefix_display":null,"first_name":"SEAN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145902,"prefix":null,"prefix_display":null,"first_name":"MARIA","nickname":null,"middle_name":null,"last_name":"GHAZAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145905,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 3164/S. 2426, Ensuring Community Access to Pharmacist Services Act H.R. 4093, S. 3848, Apples to Apples Comparison Act H.R. 4731/S. 2439, Resident Physician Shortage Reduction Act H.R. 6010/S. 1105, No UPCODE Act H.R. 6130/ S. 3267, Alzheimers Screening and Prevention Act U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (CMS-4212-P) U.S Department of Health and Human Services, Centers for Medicare & Medicaid ServicesAdvance Notice of Methodological Changes for Calendar Year (CY) 2027 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS-2026-0034) U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program (CMS-9883-P) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions to Unleash Prosperity (HTI-5) Proposed Rule (RIN 0955-AA09) U.S. Department of Health and Human Services, Office of the Assistant Secretary for Technology Policy Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care (RIN 0955-AA13)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145902,"prefix":null,"prefix_display":null,"first_name":"MARIA","nickname":null,"middle_name":null,"last_name":"GHAZAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145905,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145906,"prefix":null,"prefix_display":null,"first_name":"CLARA","nickname":null,"middle_name":null,"last_name":"KEANE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147562,"prefix":null,"prefix_display":null,"first_name":"SEAN","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/c7058672-76ad-4fa4-93ab-0817215e9323/","filing_uuid":"c7058672-76ad-4fa4-93ab-0817215e9323","filing_type":"2A","filing_type_display":"2nd Quarter - Amendment","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/c7058672-76ad-4fa4-93ab-0817215e9323/print/","filing_document_content_type":"text/html","income":null,"expenses":"70000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Scott Frey","dt_posted":"2026-09-24T12:31:17-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2033 K Street NW","registrant_address_2":"Suite 450","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401010854,"url":"https://lda.gov/api/v1/registrants/401010854/","house_registrant_id":42171,"name":"ALLIANCE FOR AGING RESEARCH","description":"Non-profit healthcare advocacy organization","address_1":"2033 K Street NW","address_2":"Suite 450","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SCOTT FREY","contact_telephone":"+1 571-289-1385","dt_updated":"2026-09-24T12:38:43.419803-04:00"},"client":{"id":196811,"url":"https://lda.gov/api/v1/clients/196811/","client_id":12,"name":"ALLIANCE FOR AGING RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-05-04"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401) -End Coverage with Evidence Development for Alzheimer's Medications and TAVR","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program -FY 27 Appropriations H.R. 9260 and pending Senate bill, Increase Funding for Programs benefitting older adults at HHS, including ASPE, NIH, CDC HRSA, ARHQ, FDA, CMS, ACL","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138576,"prefix":"ms","prefix_display":"MS.","first_name":"ADINA","nickname":null,"middle_name":"ROSE","last_name":"LASSER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/43f2532a-89be-47eb-b550-f9977094a320/","filing_uuid":"43f2532a-89be-47eb-b550-f9977094a320","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/43f2532a-89be-47eb-b550-f9977094a320/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Kristine Blackwood","dt_posted":"2026-10-13T19:36:18-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"5804 Augusta Lane","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Bethesda","registrant_state":"MD","registrant_zip":"20816","registrant":{"id":401108541,"url":"https://lda.gov/api/v1/registrants/401108541/","house_registrant_id":56515,"name":"KRISTINE BLACKWOOD LLC","description":null,"address_1":"5804 Augusta Lane","address_2":null,"address_3":null,"address_4":null,"city":"Bethesda","state":"MD","state_display":"Maryland","zip":"20816","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KRISTINE BLACKWOOD","contact_telephone":"+1 202-341-8545","dt_updated":"2026-06-29T20:43:43.620614-04:00"},"client":{"id":60166,"url":"https://lda.gov/api/v1/clients/60166/","client_id":60166,"name":"AMERICAN GERIATRICS SOCIETY","general_description":"non-profit society of geriatrics practitioners","client_government_entity":null,"client_self_select":false,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for funding the geriatrics workforce education programs at the Health Resources and Services Administration. Support for aging research programs at the National Institute on Aging in fiscal year 2027 and monitoring of H.R. 6500, the \"Continuing Appropriations and Extensions Act, 2027.\"","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146422,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"BLACKWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Support for reauthorization of geriatrics workforce enhancement and academic career award programs (HR 4262, to reauthorize programs related to health professions education, and for other purposes, Energy & Commerce Committee draft for Title VII programs reauthorization; S.4110, EMPOWER for Health Act; and S.2699, Geriatrics Workforce Improvement Act). Support for research programs at the National Institute on Aging on drivers of chronic conditions, older adult medical complexity and Alzheimer's disease and related dementias. Support for amendments to S.1799/HR 3501, \"Concentrating on High-Value Alzheimers Needs to Get to an End\" legislation to provide for shared decision making, care planning and services, and primary care quality measures in connection with cognitive screening of Medicare beneficiaries; and monitoring of H.R. 6130, the Alzheimers Screening and Prevention (ASAP) Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146422,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"BLACKWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Support for Medicare physician payment reform, including H.R.879, the Medicare Patient Access and Practice Stabilization Act of 2025 and H.R. 8163, Provider Reimbursement Stability Act (H.R. 8163); Support for amendments to S. 1799/HR 3501, \"Concentrating on High-Value Alzheimers Needs to Get to an End\" to provide for shared decision-making, care planning and services, and primary care quality measures in connection with cognitive screening for Medicare beneficiaries; and monitoring of H.R. 6130, the Alzheimers Screening and Prevention (ASAP) Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146422,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"BLACKWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/43f2532a-89be-47eb-b550-f9977094a320/","filing_uuid":"43f2532a-89be-47eb-b550-f9977094a320","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/43f2532a-89be-47eb-b550-f9977094a320/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Kristine Blackwood","dt_posted":"2026-10-13T19:36:18-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"5804 Augusta Lane","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Bethesda","registrant_state":"MD","registrant_zip":"20816","registrant":{"id":401108541,"url":"https://lda.gov/api/v1/registrants/401108541/","house_registrant_id":56515,"name":"KRISTINE BLACKWOOD LLC","description":null,"address_1":"5804 Augusta Lane","address_2":null,"address_3":null,"address_4":null,"city":"Bethesda","state":"MD","state_display":"Maryland","zip":"20816","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KRISTINE BLACKWOOD","contact_telephone":"+1 202-341-8545","dt_updated":"2026-06-29T20:43:43.620614-04:00"},"client":{"id":60166,"url":"https://lda.gov/api/v1/clients/60166/","client_id":60166,"name":"AMERICAN GERIATRICS SOCIETY","general_description":"non-profit society of geriatrics practitioners","client_government_entity":null,"client_self_select":false,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for funding the geriatrics workforce education programs at the Health Resources and Services Administration. Support for aging research programs at the National Institute on Aging in fiscal year 2027 and monitoring of H.R. 6500, the \"Continuing Appropriations and Extensions Act, 2027.\"","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146422,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"BLACKWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Support for reauthorization of geriatrics workforce enhancement and academic career award programs (HR 4262, to reauthorize programs related to health professions education, and for other purposes, Energy & Commerce Committee draft for Title VII programs reauthorization; S.4110, EMPOWER for Health Act; and S.2699, Geriatrics Workforce Improvement Act). Support for research programs at the National Institute on Aging on drivers of chronic conditions, older adult medical complexity and Alzheimer's disease and related dementias. Support for amendments to S.1799/HR 3501, \"Concentrating on High-Value Alzheimers Needs to Get to an End\" legislation to provide for shared decision making, care planning and services, and primary care quality measures in connection with cognitive screening of Medicare beneficiaries; and monitoring of H.R. 6130, the Alzheimers Screening and Prevention (ASAP) Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146422,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"BLACKWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Support for Medicare physician payment reform, including H.R.879, the Medicare Patient Access and Practice Stabilization Act of 2025 and H.R. 8163, Provider Reimbursement Stability Act (H.R. 8163); Support for amendments to S. 1799/HR 3501, \"Concentrating on High-Value Alzheimers Needs to Get to an End\" to provide for shared decision-making, care planning and services, and primary care quality measures in connection with cognitive screening for Medicare beneficiaries; and monitoring of H.R. 6130, the Alzheimers Screening and Prevention (ASAP) Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146422,"prefix":null,"prefix_display":null,"first_name":"KRISTINE","nickname":null,"middle_name":null,"last_name":"BLACKWOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d0713f03-58a0-4530-af86-49449d2e71bc/","filing_uuid":"d0713f03-58a0-4530-af86-49449d2e71bc","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/d0713f03-58a0-4530-af86-49449d2e71bc/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-10-19T10:17:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Opposition to OMB-2026-0034, Regulation for Federal Financial Assistance, which would make broad changes to the Uniform Guidance governing federal grants and cooperative agreements across federal agencies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d0713f03-58a0-4530-af86-49449d2e71bc/","filing_uuid":"d0713f03-58a0-4530-af86-49449d2e71bc","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/d0713f03-58a0-4530-af86-49449d2e71bc/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-10-19T10:17:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Opposition to OMB-2026-0034, Regulation for Federal Financial Assistance, which would make broad changes to the Uniform Guidance governing federal grants and cooperative agreements across federal agencies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/eb504afd-06cd-4cdf-842c-5940a229d8d4/","filing_uuid":"eb504afd-06cd-4cdf-842c-5940a229d8d4","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/eb504afd-06cd-4cdf-842c-5940a229d8d4/print/","filing_document_content_type":"text/html","income":null,"expenses":"65000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Scott Frey","dt_posted":"2026-10-19T14:20:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2033 K Street NW","registrant_address_2":"Suite 450","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401010854,"url":"https://lda.gov/api/v1/registrants/401010854/","house_registrant_id":42171,"name":"ALLIANCE FOR AGING RESEARCH","description":"Non-profit healthcare advocacy organization","address_1":"2033 K Street NW","address_2":"Suite 450","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SCOTT FREY","contact_telephone":"+1 571-289-1385","dt_updated":"2026-09-24T12:38:43.419803-04:00"},"client":{"id":196811,"url":"https://lda.gov/api/v1/clients/196811/","client_id":12,"name":"ALLIANCE FOR AGING RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-05-04"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.3251/S 4440 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement -Update CMS Long stay antipsychotic Quality measure -Update FDA Antipsychotic black box warning -Funding for NIH (HR 9260) -PASTEUR Act (HR 7352/S 4975) -Biosimilar Access and Affordability Act (HR10628/S5571) -CMS Fixed Dose Combination Therapies proposed policy -OMB Proposed Uniform Guidance on Federal Grantmaking (HR 6500) -Alzheimer's Early Detection Act (HR 9823) -CMS reporting requirements for Medicare Prescription Payment Program (HR 9260) -CMS Trans Catheter Aortic Valve Replacement NCD proposal","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"-Implementation of Medicare Part D beneficiary affordability provisions -Nursing home quality measures -Implementation of the Medicare Direct Negotiation Program and its impact on older adults -Utilization management reform in Medicare -Increasing Medication Access for Seniors Act (H.R.6401) -End Coverage with Evidence Development for Alzheimer's Medications and TAVR","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program -FY 27 Appropriations H.R. 9260 and pending Senate bill, Increase Funding for Programs benefitting older adults at HHS, including ASPE, NIH, CDC HRSA, ARHQ, FDA, CMS, ACL -FY 27 Appropriations - oppose OMB uniform Guidance on federal grantmaking","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":149533,"prefix":null,"prefix_display":null,"first_name":"SCOTT","nickname":null,"middle_name":null,"last_name":"FREY","suffix":null,"suffix_display":null},"covered_position":"Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}